08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

ThioLogics, Albumedix deal

Albumedix and ThioLogics partnered exclusively to commercialize albumin-drug conjugates, which the companies say will have improved delivery and pharmacokinetic properties. The partners will use Albumedix’s Veltis albumin-based drug delivery technology and ThioLogics’ site-specific Next Generation...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Eleven Biotherapeutics, Albumedix deal

Albumedix acquired Eleven’s Supermin albumin variant technology. Eleven will receive an undisclosed upfront payment, and the companies will share commercialization income. Albumedix is a subsidiary of Novozymes A/S (CSE:NZYM B, Bagsvaerd, Denmark). The partners declined...